News for Orexigen Therapeutics, Inc. - Google Finance

OREXIGEN THERAPEUTICS, INC. : Orexigen Therapeutics to Present at the ...

Fri, 17 May 2013 20:07:23 GMT

OREXIGEN THERAPEUTICS, INC. : Orexigen Therapeutics to Present at the ...
4-traders (press release) - May 17, 2013

SAN DIEGO, May 17, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the UBS Global Healthcare Conference in New York.

Arena Pharmaceuticals, Inc. (ARNA), Vivus, Inc. (VVUS) & Orexigen ...

Thu, 16 May 2013 18:29:14 GMT

Arena Pharmaceuticals, Inc. (ARNA), Vivus, Inc. (VVUS) & Orexigen ...
Insider Monkey (blog) - May 16, 2013

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) It wasn't that long ago that obesity drugs were considered a lifestyle drug. Doctors, the Food and Drug Administration, and insurers believed losing weight was a vanity issue.

Orexigen Therapeutics, Inc. (NASDAQ:OREX) Investor Alert: Investigation over ...

Tue, 14 May 2013 12:21:34 GMT

Orexigen Therapeutics, Inc. (NASDAQ:OREX) Investor Alert: Investigation over ...
SBWire (press release) - May 14, 2013

An investigation for current long-term investors in shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) over potential wrongdoing by certain officers and directors of Orexigen Therapeutics was announced and NASDAQ:OREX stockholders should contact ...

NASDAQ Decliners Watch List: Rockwell Medical, Inc. (NASDAQ:RMTI), VIVUS ...

Wed, 15 May 2013 20:55:42 GMT

NASDAQ Decliners Watch List: Rockwell Medical, Inc. (NASDAQ:RMTI), VIVUS ...
SBWire (press release) - May 15, 2013

Orexigen Therapeutics, Inc. (NASDAQ:OREX) a biopharmaceutical company that focuses on the development of pharmaceutical product candidates for the treatment of obesity closed down in its previous session (-3.29%) on 789,604 shares traded after ...

Orexigen Therapeutics praises new research report on obesity prevention policies

Fri, 26 Apr 2013 08:13:01 GMT

Orexigen Therapeutics praises new research report on obesity prevention policies
News-Medical.net - Apr 26, 2013

Regarding the report "The Long Term Returns of Obesity Prevention Policies" unveiled this week by the Campaign to End Obesity (CEO), Orexigen Therapeutics, Inc. (Nasdaq: OREX) issued the following statement: Orexigen commends CEO as well as the ...

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), Orexigen Therapeutics, Inc ...

Tue, 23 Apr 2013 20:04:50 GMT

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), Orexigen Therapeutics, Inc ...
SBWire (press release) - Apr 23, 2013

New York, NY -- (SBWIRE) -- 04/23/2013 -- Growing Stock Report expands its NASDAQ Gainers Weekly Watch List adding Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), Orexigen Therapeutics, Inc. (NASDAQ:OREX), and Astex Pharmaceuticals, Inc.

Orexigen Therapeutics Reports Financial Results for the First Quarter Ended ...

Wed, 08 May 2013 20:05:18 GMT

Orexigen Therapeutics Reports Financial Results for the First Quarter Ended ...
MSN Money - May 8, 2013

SAN DIEGO, May 8, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. OREX, a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the first quarter ended March 31, 2013.

Traders Alert: JDS Uniphase, Morgan Stanley, Orexigen Therapeutics, Masco

Wed, 24 Apr 2013 15:22:24 GMT

Traders Alert: JDS Uniphase, Morgan Stanley, Orexigen Therapeutics, Masco
Mesh Press (press release) - Apr 24, 2013

Orexigen Therapeutics, Inc.(NASDAQ:OREX) shares gained 4.29% to $6.57. The company, on Mar. 13, posted fourth-quarter net loss of $32.5 million or $0.41 per share, wider than $4.3 million or $0.09 per share in the previous year quarter.

VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): A Belviq Battle

Tue, 14 May 2013 14:35:32 GMT

VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): A Belviq Battle
Insider Monkey (blog) - May 14, 2013

Orexigen Therapeutics, Inc. (NASDAQ:OREX)'s weight loss drug Contrave is undergoing an FDA-required cardiovascular safety study.

SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an ...

Mon, 13 May 2013 14:35:46 GMT

SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an ...
MarketWatch (press release) - May 13, 2013

NEW YORK, May 13, 2013 (BUSINESS WIRE) -- Levi & Korsinsky, LLP is investigating Orexigen Therapeutics, Inc. (nasdaqgs:OREX), and its Board of Directors, in connection with possible claims of breaches of fiduciary duty.